FinscoFinsco

Haemonetics (US.HAE)

Capital Allocation Audit · Period: 2010 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.HAE · YoY: 2026 ANNUAL vs 2025 ANNUAL

MetricValueYoY
FCF Conversion88.8%↑
ROE12.2%↓
Cash Conversion301.3%↑
D/E Ratio1.54→
Gross Margin59.0%↑
US.HAE (Haemonetics) | YoY: 2026 ANNUAL vs 2025 ANNUAL


Metric            Value  YoY
----------------------------
FCF Conversion    88.8%    ↑
ROE               12.2%    ↓
Cash Conversion  301.3%    ↑
D/E Ratio          1.54    →
Gross Margin      59.0%    ↑
Key Metrics
US.HAE (Haemonetics) | YoY: 2026 ANNUAL vs 2025 ANNUAL
Metric Value YoY
----------------------------
FCF Conversion 88.8% ↑
ROE 12.2% ↓
Cash Conversion 301.3% ↑
D/E Ratio 1.54 →
Gross Margin 59.0% ↑

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies